S&P 500   4,536.36 (+0.37%)
DOW   35,616.44 (+0.45%)
QQQ   374.72 (-0.20%)
AAPL   148.79 (+0.02%)
MSFT   307.14 (-0.35%)
FB   340.74 (+0.22%)
GOOGL   2,838.33 (-0.92%)
TSLA   866.28 (+0.23%)
AMZN   3,414.54 (-0.86%)
NVDA   220.38 (-1.13%)
BABA   177.40 (+0.23%)
NIO   39.70 (-0.82%)
CGC   14.11 (-1.60%)
GE   105.16 (+0.41%)
AMD   116.15 (-0.15%)
MU   68.39 (+1.21%)
T   25.93 (+1.33%)
F   15.91 (+3.18%)
ACB   7.55 (+1.34%)
DIS   170.56 (-0.36%)
PFE   42.83 (+1.76%)
BA   216.88 (+0.42%)
AMC   40.78 (-0.05%)
S&P 500   4,536.36 (+0.37%)
DOW   35,616.44 (+0.45%)
QQQ   374.72 (-0.20%)
AAPL   148.79 (+0.02%)
MSFT   307.14 (-0.35%)
FB   340.74 (+0.22%)
GOOGL   2,838.33 (-0.92%)
TSLA   866.28 (+0.23%)
AMZN   3,414.54 (-0.86%)
NVDA   220.38 (-1.13%)
BABA   177.40 (+0.23%)
NIO   39.70 (-0.82%)
CGC   14.11 (-1.60%)
GE   105.16 (+0.41%)
AMD   116.15 (-0.15%)
MU   68.39 (+1.21%)
T   25.93 (+1.33%)
F   15.91 (+3.18%)
ACB   7.55 (+1.34%)
DIS   170.56 (-0.36%)
PFE   42.83 (+1.76%)
BA   216.88 (+0.42%)
AMC   40.78 (-0.05%)
S&P 500   4,536.36 (+0.37%)
DOW   35,616.44 (+0.45%)
QQQ   374.72 (-0.20%)
AAPL   148.79 (+0.02%)
MSFT   307.14 (-0.35%)
FB   340.74 (+0.22%)
GOOGL   2,838.33 (-0.92%)
TSLA   866.28 (+0.23%)
AMZN   3,414.54 (-0.86%)
NVDA   220.38 (-1.13%)
BABA   177.40 (+0.23%)
NIO   39.70 (-0.82%)
CGC   14.11 (-1.60%)
GE   105.16 (+0.41%)
AMD   116.15 (-0.15%)
MU   68.39 (+1.21%)
T   25.93 (+1.33%)
F   15.91 (+3.18%)
ACB   7.55 (+1.34%)
DIS   170.56 (-0.36%)
PFE   42.83 (+1.76%)
BA   216.88 (+0.42%)
AMC   40.78 (-0.05%)
S&P 500   4,536.36 (+0.37%)
DOW   35,616.44 (+0.45%)
QQQ   374.72 (-0.20%)
AAPL   148.79 (+0.02%)
MSFT   307.14 (-0.35%)
FB   340.74 (+0.22%)
GOOGL   2,838.33 (-0.92%)
TSLA   866.28 (+0.23%)
AMZN   3,414.54 (-0.86%)
NVDA   220.38 (-1.13%)
BABA   177.40 (+0.23%)
NIO   39.70 (-0.82%)
CGC   14.11 (-1.60%)
GE   105.16 (+0.41%)
AMD   116.15 (-0.15%)
MU   68.39 (+1.21%)
T   25.93 (+1.33%)
F   15.91 (+3.18%)
ACB   7.55 (+1.34%)
DIS   170.56 (-0.36%)
PFE   42.83 (+1.76%)
BA   216.88 (+0.42%)
AMC   40.78 (-0.05%)
NASDAQ:HRMY

Harmony Biosciences Stock Forecast, Price & News

$41.95
+0.05 (+0.12 %)
(As of 10/20/2021 02:51 PM ET)
Add
Compare
Today's Range
$41.67
$42.93
50-Day Range
$30.16
$39.40
52-Week Range
$25.09
$52.74
Volume48,772 shs
Average Volume254,582 shs
Market Capitalization$2.39 billion
P/E Ratio182.39
Dividend YieldN/A
Beta-0.46
30 days | 90 days | 365 days | Advanced Chart
Receive HRMY News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Harmony Biosciences logo

About Harmony Biosciences

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRMY
Employees
150
Year Founded
N/A

Sales & Book Value

Annual Sales
$159.74 million
Cash Flow
$0.84 per share
Book Value
$1.71 per share

Profitability

Net Income
$-36.94 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.39 billion
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.50 out of 5 stars

Medical Sector

115th out of 1,360 stocks

Pharmaceutical Preparations Industry

48th out of 667 stocks

Analyst Opinion: 2.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -












Harmony Biosciences (NASDAQ:HRMY) Frequently Asked Questions

Is Harmony Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Harmony Biosciences stock.
View analyst ratings for Harmony Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Harmony Biosciences?

Wall Street analysts have given Harmony Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Harmony Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Harmony Biosciences?

Harmony Biosciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 1,410,000 shares, an increase of 52.1% from the September 15th total of 927,100 shares. Based on an average daily trading volume, of 353,000 shares, the days-to-cover ratio is currently 4.0 days. Currently, 6.4% of the company's shares are short sold.
View Harmony Biosciences' Short Interest
.

When is Harmony Biosciences' next earnings date?

Harmony Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Harmony Biosciences
.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its earnings results on Monday, August, 9th. The company reported $0.24 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.18 by $0.06. The firm had revenue of $73.82 million for the quarter, compared to the consensus estimate of $70.85 million. Harmony Biosciences had a trailing twelve-month return on equity of 66.92% and a net margin of 9.86%.
View Harmony Biosciences' earnings history
.

What price target have analysts set for HRMY?

2 Wall Street analysts have issued twelve-month price targets for Harmony Biosciences' shares. Their forecasts range from $43.00 to $57.00. On average, they expect Harmony Biosciences' share price to reach $50.00 in the next twelve months. This suggests a possible upside of 19.0% from the stock's current price.
View analysts' price targets for Harmony Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Harmony Biosciences' key executives?

Harmony Biosciences' management team includes the following people:
  • Mr. Jeffrey S. Aronin, Founder & Non-Exec. Chairman (Age 53, Pay $31.2k)
  • Mr. John Charles Jacobs M.B.A., Pres, CEO & Director (Age 53, Pay $933.94k)
  • Dr. Jeffrey M. Dayno, Chief Medical Officer (Age 64, Pay $734.25k) (LinkedIn Profile)
  • Mr. Jeffrey Dierks M.B.A., Chief Commercial Officer (Age 49, Pay $482.45k) (LinkedIn Profile)
  • Mr. Sandip S. Kapadia CPA, M.B.A., Chief Financial Officer (Age 51)
  • Mr. David Bradshaw, Head of Technical Operations
  • Ms. Sharon Goldbach, Head of Facilities Operations & Exec. Admin.
  • Ms. Lisa M. Caperelli, Head of Investor Relations
  • Mr. Christian Ulrich, Gen. Counsel
  • Ms. Tricia Glover, Chief Compliance Officer

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), The Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

When did Harmony Biosciences IPO?

(HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO.

What is Harmony Biosciences' stock symbol?

Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY."

How do I buy shares of Harmony Biosciences?

Shares of HRMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harmony Biosciences' stock price today?

One share of HRMY stock can currently be purchased for approximately $42.01.

How much money does Harmony Biosciences make?

Harmony Biosciences has a market capitalization of $2.39 billion and generates $159.74 million in revenue each year. The company earns $-36.94 million in net income (profit) each year or $0.21 on an earnings per share basis.

How many employees does Harmony Biosciences have?

Harmony Biosciences employs 150 workers across the globe.

What is Harmony Biosciences' official website?

The official website for Harmony Biosciences is www.harmonybiosciences.com.

Where are Harmony Biosciences' headquarters?

Harmony Biosciences is headquartered at 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462.

How can I contact Harmony Biosciences?

Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The company can be reached via phone at 484-539-9800 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.